Fractyl Health, Inc. Common Stock (GUTS) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GUTS Revenue Growth
GUTS Revenue Analysis (2019–2025)
As of May 8, 2026, Fractyl Health, Inc. Common Stock (GUTS) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, GUTS's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $120,000 in 2023.
When compared to Healthcare sector peers including NVAX (-52.5% YoY), RNAC (-94.8% YoY), and RMTI (+17690.7% YoY), GUTS has underperformed the peer group in terms of revenue growth. Compare GUTS vs NVAX →
GUTS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GUTSCurrent | $0 | -100.0% | - | - | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% | |
 RNAC | $3M | -94.8% | -30.0% | -3099.9% | |
 RMTI | $69M | +17690.7% | +2.2% | -6.8% |
GUTS Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $-96,816,000 | - |
| 2024 | $93K | -22.5% | $43K | 46.2% | $-93,531,000 | -100571.0% |
| 2023 | $120K | - | $43K | 35.8% | $-50,836,000 | -42363.3% |
| 2022 | $0 | - | $-452,000 | - | $-49,385,000 | - |
| 2021 | $0 | - | $0 | - | $-36,928,000 | - |
| 2020 | $0 | - | $-770,000 | - | $-28,961,000 | - |
| 2019 | $0 | - | $-893,000 | - | $-29,919,000 | - |
See GUTS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GUTS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GUTS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGUTS — Frequently Asked Questions
Quick answers to the most common questions about buying GUTS stock.
Is GUTS's revenue growth accelerating or slowing?
GUTS revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is GUTS's long-term revenue growth rate?
Fractyl Health, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is GUTS's revenue distributed by segment?
GUTS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.